Get started

GSK

BIOC A safe and excellent opportunity by all standardsWhat the global atmosphere is witnessing is the escalation of the new monkey epidemic, and also the raising of drug prices in Egypt by a decision of the Egyptian Medicine Authority. Entering the diverse winter season can be more difficult than summer is a paradise for Egyptian pharmaceutical companies listed on the Egyptian Stock Exchange From my personal experience, I exited gold today on the date of publication of this theory, and tomorrow I will buy an amount of shares amounting to 10 thousand shares. I put this process into history for success or otherwise, and I hope to achieve 25 to 30% returns on that money.
EGX:BIOCLong
by atuumra
1
BICO risen from 27 to 41 in 5 monthsRapid change with almost certain assistance from its parent company What happened during the past period is like a miracle. The company transformed after the first quarter results showed huge losses and embezzlement charges that resulted in restructuring. After the distribution of closed dividends per share was suspended at 0.75 until liquidity was available, and liquidity was available quickly. I believe that financing was provided by the parent company in exchange for an export share and benefiting from the currency difference after the delay in the Medicine Authority’s decision to move the exchange rate. The pending dividends were issued to shareholders and we await the second-quarter results, which look promising I expect the stock to rise to 30 pounds during the month of 8, and the trend is towards 40 in January 2025.
EGX:BIOCLong
by atuumra
GSK Death Cross my be hugely bullish after all !GlaxoSmithKlein (GSK) just formed a Death Cross on the 1D time-frame, which is when the 1D MA50 (blue trend-line) crosses below the 1D MA200 (orange trend-line). This is technically a bearish pattern but last time it formed (March 24 2020) was exactly on the bottom of the COVID crash and the price recovered rapidly. That was of course in the aftermath of the massive economic package in an attempt to support the economy from the lockdown but even now there is upside potential and some levels to consider on the short-term. As you see, since April 11, the stock has been trading within a perfect Channel Down. This indicates a systematic downtrend. As long as the 1D MA50 holds, such rises are sell opportunities towards a Lower Low, in which case its on the 0.236 now. Since we are trading so close to the 1D MA50, a tight sell now with the SL located at the top of the Channel Down, has an excellent Risk/ Reward ratio. Similarly, if the price breaks above the top of the Channel Down, the R/R is favorable in going on a tight buy targeting the upper Fibs and ultimately the 47.00 Resistance. Notice how the 1D RSI bounced off near the 30.00 oversold level, which has initiated massive rebounds another 4 times within the long-term Channel Up. -------------------------------------------------------------------------------------------------------- ** Please support this idea with your likes and comments, it is the best way to keep it relevant and support me. ** --------------------------------------------------------------------------------------------------------
NYSE:GSK
by TradingShot
1
GSK Glaxo Smith Kline - Multi Year Lows, A Bargain To Be Bought?GSK is trading around the multi year lows having bounced off of the long term support zone at 1300. I think this is a relative bargain at these levels with GSK being one of the Big Pharma Companies that is still trading way below the starting price for the year. Pfizer, Johnson & Johnson and Roche are all either positive or around net zero YTD. Novartis is trading slightly lower and so is Merck and Co but not to the extent of GSK making it a bargain in the big Pharma world. Dividend Yield is current around 5.3% which is high enough to warrant it being a good income stock even if the share price was to remain flat for the next 5 years. Upside targets are at 1720 which is the next major price resistance zone and and 1850 which is the 18 year highs (formed in 2019). There is a chance that price could fall back down to 1300 or even the multi year lows at 1235 which would make for a real bargain. But even at the current price of 1378.00 I think over the next 5 years this is a good stock to hold.
LSE:GSKLong
by DOAFK
BVXV innovative COVID-19 nanosized antibodiesBiondVax has signed definitive agreements with the Max Planck Society and the University Medical Center Göttingen to enter into a strategic collaboration for the development and commercialization of innovative COVID-19 nanosized antibodies (NanoAbs). NanoAbs exhibited in-vitro neutralization of all COVID-19 variants of concern including Delta, and based on in-silico studies, Omicron, at significantly lower dose levels than existing antibody treatments. i know that this is an early stage, but today they announced also that the Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors. just to make an idea, GSK has a Market Cap of 111Bil and Jay Green went to a company that has a mk cap of 35Mil. They also had a public offering at the price of $2.36. 52 Week Range 1.36 - 7.22 My price target is $6
BLong
by TopgOptions
Another Big Pharma Finding The BottomBased on historical movement, the trough could occur anywhere in the larger red box. The final targets are in the green boxes. The pending top should occur within the larger green box as has been the historical case. Half of all movement has ended in the smaller green box. In this instance, the signal indicated BUY on September 17, 2021 with a closing price of 38.93. If this instance is successful, that means the stock should rise to at least 39.62 which is the bottom of the larger green box. Three-quarters of all successful signals have the stock rise 4.748% from the signal closing price. This percentage is the bottom of the smaller green box. Half of all successful signals have the stock rise 6.534% which is the end point of the black dotted arrow. One-quarter of all successful signals have the stock rise 9.869% from the signal closing price which is the top of the smaller green box. The maximum rise on record would see a move to the top of the larger green box. These are the same concepts for the levels in the red boxes as well. The ends/vertical sides of the boxes are determined in a similar fashion. The peak of the rise can occur as soon as the next trading bar after signal close, while the max rise occurs within the limit of study at 35 trading bars after the signal. A 1% rise must occur over the next 35 trading bars in order to be considered a success. Three-quarters of successful movement occur after at least 20 trading bars; half occur within 30 trading bars, and one-quarter require at least 33 trading bars. The black dotted arrow represents median historical movement. Medians are a good metric, but they are just one of many I use when forecasting future movement. As always, the stock could decline the very next bar after the signal without looking back (therefore the red boxes would not come into play) or the stock may never decline (and the green boxes may never come into play).
NYSE:GSKLong
by StockSignaler
Glaxosmithkline testing golden resistance level 1431.5Glaxosmithkline ($GSK) testing the golden resistance level 1431.5 standing outside of the upper daily Bollinger Band. This level previously reversed Glaxosmithkline down in December of 2020 and in January of this year. Selected Alpha ranks the reversal factor of this resistance level 25 points – making it the strongest golden tracked by the system at the moment. With both the daily RSI and the daily Stochastic in the overbought territory – expect the downard correction from the resistance level 1431.5.
LSE:GSKShort
by SelectedAlpha
1
GSK Intraday Entry *Breakout Pattern*I previously posted a longterm stock position that I added to my portfolio. This was GSK (GlaxoSmithKline) which is trading at the lower levels of its range and has good growth potential but also a sturdy dividend yield of more than 5% each year. This stock has seen some strong bullish momentum this week and has broken out of a consolidation structure. The bearish trendline was broken and price is now retesting the trendline and looking for support. In this current area we have the daily pivot level and also 15minute and 1hr 50EMA's for support. I think if the trendline now holds strong, price will go on to climb up to new yearly highs of 1480p where resistance lies.
LSE:GSKLong
by DOAFK
2
Long Gild - Covid Drug ($MRNA $GSK $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com Gild Entry $62 area Target 1 $67 Target 2 $71 stoploss $59 Why this play? Trump used Gild's drug as part of his treatment, if he pulls thru with a full recovery. they will probably start pumping the news about this company and it'll finally have enough momentum to move back to the upside. What is Gild? Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Notable price upgrades Sep-30-20 Resumed Jefferies Buy $78 Sep-15-20 Upgrade Maxim Group Hold → Buy $88
NASDAQ:GILDLong
by WallSt007
3
Long and hold $GSK ($MRNA $GILD $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com GSK Entry $39.70 Target 1 $42.45 Target 2 $45.50 Target 3 $48 stoploss 38.70 Why this play? There are 4 general approaches to the Covid vaccine. 1.A "killed" coronavirus that will get recognized as foreign matter in the blood. (Sinovac/Dynavax) 2.Coronavirus proteins themselves, produced industrially in outside cell cultures, which will be recognized as foreign matter in the blood. (GlaxoSmithKline/Sanofi, Novavax) 3.A different virus (human or ape adenovirus, measles, etc) that is engineered to include genetic components coding for the SARS-CoV-2 spike proteins, which causes the body to then produce them. (CanSino, Oxford, J&J, Merck/Themis) 4.DNA or RNA that will be taken up by cells and will cause them to make coronavirus proteins. (Moderna, Innovio, BioNTech/Pfizer) GSK is #2, there is only 1 other big company doing this approach and that is NVAX. We are betting on the fact that if they are successful, they could have super run like NVAX. What is GSk? www.gsk.com GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
NYSE:GSKLong
by WallSt007
ridethepig | GILD 2019-nCoV TargetA good time to review the previous floor at 60.xx that we have been tracking for almost a year in $GILD. Here taking the latest misses in Q4 Earnings with a pinch of salt as the red carpet has been rolled out for Gild via China. Once again another buying opportunity given the latest progress around Phase III clinical trials: On the Remdesivir (GS-5734) side, this is their free pass into the Chinese Healthcare system. Models will need to start quickly repricing revenue from the Hep B cases in China. GILD will do the heavy lifting here, +/- $20 upside available on the headline for FDA approval which looks around the corner. Flow-wise, the initial target area from the latest technical break comes into play at 86.xx (+25% from current levels). As usual thanks for keeping the support coming with likes, comments and etc!
NASDAQ:GILDLong
by ridethepig
2
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings. Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best! We took a long position at $82.00 several weeks ago. We feel the stock is worth at minimum, $150.00 all day long. KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales. Holding for the almost 3% Dividend and for the stock price appreciation into the future. 250,000 LONG @ $82.00 Best of Luck Everyone!
NYSE:MRKLong
by UnknownUnicorn3159981